ACST - Acasti Pharma Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.9600
+0.2500 (+14.62%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.7100
Open1.7200
Bid0.0000 x 4000
Ask0.0000 x 1100
Day's Range1.7386 - 2.1000
52 Week Range0.4300 - 2.1000
Volume8,534,602
Avg. Volume852,030
Market Cap155.686M
Beta (3Y Monthly)1.14
PE Ratio (TTM)N/A
EPS (TTM)-1.2240
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.52
Trade prices are not sourced from all markets
  • Bausch Gains 38.9% YTD on Product Launches & Debt Reduction
    Zacks18 days ago

    Bausch Gains 38.9% YTD on Product Launches & Debt Reduction

    Bausch (BHC) is currently focusing on widening its ophthalmology and dermatology portfolio.

  • Benzinga27 days ago

    Acasti Pharma Trades Higher Despite 'Material Uncertainty'

    The company recorded milestones related to its Phase 3 clinical trials and achieved 100% patient randomization in the TRILOGY clinical trials. Acasti's loss for fiscal 2019 expanded from $21.5 million in the prior year to $51.6 million due to higher R&D costs for the TRILOGY Phase 3 program and other financial expenses.

  • ACCESSWIRE27 days ago

    Acasti Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / June 26, 2019 / Acasti Pharma, Inc. (NASDAQ: ACST ) will be discussing their earnings results in their 2019 Fourth Quarter Earnings to be held on June, 26 2019 at 1:00 PM Eastern ...

  • GlobeNewswire27 days ago

    Acasti Pharma Provides Fiscal 2019 Year-End Business Update

    LAVAL, Québec, June 26, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today provided a business update and announced its financial results for the fiscal year ending March 31, 2019. Jan D’Alvise, president and CEO of Acasti Pharma, commented, “Fiscal 2019 was an eventful year for the Company as we achieved several key milestones related to our ongoing Phase 3 clinical trials, which remain on schedule and within budget.

  • GlobeNewswire29 days ago

    Acasti Pharma Awarded Notice of Allowance for a Second Patent in China Covering CaPre’s Omega-3 Phospholipid Composition

    LAVAL, Québec, June 24, 2019 -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research,.

  • GlobeNewswirelast month

    Acasti Pharma Schedules Fourth Quarter and Fiscal 2019 Conference Call

    Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced that it will host a conference call at 1:00 PM Eastern Time on Wednesday, June 26, 2019 to discuss the Company’s financial results for the fourth quarter and year-ended March 31, 2019, as well as the Company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 877-407-8031 for U.S. callers or +1 201-689-8031 for international callers, or on the Company’s News and Investors section of the website: https://www.acastipharma.com/investors/.

  • GlobeNewswire2 months ago

    Acasti Pharma Announces TRILOGY 2 Trial Has Achieved its 100% Patient Randomization Target in Patients with Severe Hypertriglyceridemia

    Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced that the Company’s TRILOGY 2 trial studying CaPre in patients with severe hypertriglyceridemia has achieved 100% patient randomization.  This follows the Company’s prior announcement in April 2019 that the Company’s TRILOGY 1 trial had achieved 100% patient randomization.

  • GlobeNewswire2 months ago

    Acasti Issues Shares in Settlement of Claims with Former Chief Executive Officer

    LAVAL, Québec, May 23, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announced that it has completed the previously disclosed issuance of 900,000 common shares from treasury to its former chief executive officer (the “Former CEO”) pursuant to the terms of a settlement agreement announced by the Company on May 10, 2019. Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk.

  • GlobeNewswire2 months ago

    Acasti Pharma to Present at the 20th Annual B. Riley FBR Institutional Investor Conference

    LAVAL, Québec, May 21, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it will be presenting at the 20th Annual B. Riley FBR Institutional Investor Conference on Wednesday, May 22nd, at 9:00 AM, PST. The conference is being held May 22-23, 2019 at The Beverly Hilton in Beverly Hills, California. Jan D’Alvise, Chief Executive Officer of Acasti, will be presenting a company overview as well as meeting with investors.

  • GlobeNewswire2 months ago

    Acasti Pharma Awarded Notices of Allowance for Additional Composition & Use Patents in Mexico, Chile and Israel

    LAVAL, Québec, May 15, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it has received Notices of Allowance for both composition of matter and method of use patents by the Mexican, Chilean and the Israeli Patent Offices. Israel, Mexico and Chile each represent important markets for potential commercialization of CaPre. Acasti’s prescription drug candidate, CaPre, is a highly purified omega-3 phospholipid concentrate derived from krill oil, and is being developed to treat severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis.

  • GlobeNewswire2 months ago

    Acasti Settles Claims with Former Chief Executive Officer

    LAVAL, Québec, May 10, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), today announced that it has settled regarding claims made against the Company by its former chief executive officer (the “Former CEO”) in respect of the termination of his employment. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti Pharma to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.

  • GlobeNewswire3 months ago

    Acasti Pharma CEO to Present at the ThinkEquity Conference on May 2nd in New York City

    Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced that Jan D'Alvise, President and Chief Executive Officer, is scheduled to present at the ThinkEquity Conference on Thursday, May 2nd, at 3:00 PM Eastern Time, which is being held at The Mandarin Oriental Hotel in New York City. Acasti Pharma’s prescription drug candidate, CaPre, is a highly purified omega-3 phospholipid concentrate derived from krill oil and is being developed to treat severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis.

  • GlobeNewswire3 months ago

    Acasti Pharma Announces TRILOGY 1 Trial Has Achieved 100% Patient Randomization in Patients with Severe Hypertriglyceridemia

    Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced that the Company’s two on-going Phase 3 TRILOGY trials (TRILOGY 1 and TRILOGY 2) have exceeded a combined 89% patient randomization, and more than 40% of the patients in both trials have completed their 6-month treatment plan. With the expected approximate 1 month of data clean-up following the “last patient out”, topline results for TRILOGY 1 are expected in December. Pierre Lemieux, Ph.D., COO and CSO of Acasti, commented, “We are very pleased to announce that our two TRILOGY Phase 3 trials are proceeding well and according to plan.

  • GlobeNewswire4 months ago

    Acasti Pharma Announces Publication of CaPre Bioavailability Study in Leading Peer-Reviewed Journal

    Further validates prior study results demonstrating that the bioavailability of CaPre is significantly better than LOVAZA when taken with a low-fat meal LAVAL, Québec,.

  • GlobeNewswire4 months ago

    Acasti Pharma to Present at the 2019 Spring Investor Summit in New York City on April 2nd

    Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the Company’s President and CEO, Jan D’Alvise, is scheduled to present at the 2019 Spring Investor Summit on Tuesday, April 2, 2019 at 1:30 pm Eastern Time at The Essex House in New York City. The Spring Investor Summit will take place in New York City at the Essex House on April 1st and 2nd.

  • GlobeNewswire4 months ago

    Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th

    Acasti’s prescription drug candidate, CaPre, is a highly purified omega-3 phospholipid concentrate derived from krill oil, and is being developed to treat severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis. Its omega-3s, principally EPA and DHA, are either “free” or bound to phospholipids, which allows for better absorption into the body.

  • GlobeNewswire5 months ago

    Acasti Pharma Recognized in TSX Venture Exchange’s 2019 Venture 50

    Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announces it has been recognized  by the TSX Venture Exchange  in its “2019 Venture 50,” a ranking of the strongest companies on TSX Venture Exchange by share price, trading volume and market capitalization.

  • Associated Press5 months ago

    Acasti: Fiscal 3Q Earnings Snapshot

    The Laval, Quebec-based company said it had a loss of 5 cents per share. The company's shares closed at 91 cents. A year ago, they were trading at $1.02. _____ This story was generated by Automated Insights ...

  • GlobeNewswire5 months ago

    Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019

    LAVAL, Québec, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today provided a business update and announced its operating and financial results for the fiscal third quarter ended December 31, 2018. Jan D’Alvise, president and CEO of Acasti Pharma, commented, “We continue to make rapid progess on our TRILOGY Phase 3 trials, and based on current trends we remain on track to report topline results by the end of this year.

  • GlobeNewswire5 months ago

    Acasti Pharma Schedules Third Quarter Fiscal 2019 Conference Call

    Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it will host a conference call at 1:00 PM Eastern Time on Thursday, February 14, 2019 to discuss the Company’s financial results for the fiscal third quarter ended December 31, 2018, as well as the Company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 866-682-6100 for U.S. callers or +1 862-298-0702 for international callers, or on the Company’s News and Investors section of the website: https://www.acastipharma.com/investors/.

  • ACCESSWIRE6 months ago

    4 Healthcare Stocks Looking To Set January Highs

    CORAL GABLES, FL/ ACCESSWIRE / January 9, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. Given that the world's population is consistently increasing, and resources are diminishing, access to healthcare is something crucial to the health and wellness of every living person, presenting a dire need for companies on a global scale. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare.

  • GlobeNewswire6 months ago

    Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office

    LAVAL, Québec, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced a Certificate for a European Patent has been issued by the European Patent Office. Pierre Lemieux, Ph.D., COO and CSO of Acasti, commented, “This is an important milestone for Acasti, as the allowance of a patent in a major jurisdiction such as Europe further strengthens and expands the Company’s intellectual property portfolio.

  • GlobeNewswire7 months ago

    Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Has Now Exceeded 65% Randomization, and More Than 100 Patients ( 20%) Have Completed Their 6 Month Treatment Plan

    LAVAL, Québec, Dec. 31, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced that the two Phase 3 TRILOGY trials have now exceeded 65% patient randomization, and more than 100 patients have completed their 6 month treatment plan. Jan D’Alvise, president and CEO of Acasti Pharma, commented, “We are pleased to announce that more than 20% of patients in the TRILOGY program have already completed their 6 month treatment plans. Additionally, Acasti Pharma today announced that on December 26, 2018, it received written notification from the Nasdaq Listing Qualifications Department (“Nasdaq”) for failing to maintain a minimum bid price of U.S.$1.00 per share for the last 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2) – bid price (the “Minimum Bid Price Rule”).

  • Generic Industry on Path to Recovery: 3 Hot Picks for 2019
    Zacks7 months ago

    Generic Industry on Path to Recovery: 3 Hot Picks for 2019

    The stability in the industry sets the stage for players to get back on growth track. Here we discuss three stocks picks from the industry.

  • GlobeNewswire7 months ago

    Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia

    LAVAL, Québec, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced it has reached the enrollment targets for its TRILOGY phase 3 trials.  In total, over 1,450 patients have been enrolled at 150 clinical sites across the U.S., Canada and Mexico. Jan D’Alvise, president and CEO of Acasti Pharma, commented, “We are pleased to report we have achieved our planned enrollment targets on schedule.  Additionally, as of December 19, 2018, more than 60% of the required total of 500 patients for the two studies have been randomized.  Additional patients may still be added to the TRILOGY program as needed early next year to achieve final randomization targets.